Panaxia Global has received official approval for the EU-GMP standard for its production facility in Malta from EU Health Authority.
Dr. Dadi Segal, CEO of Panaxia: “The EU-GMP Standard granted to our facility in Malta is a significant regulatory achievement and a result of an in-depth and lengthy audit process by the European Health Authority. It will enable us to export our products to markets that Israel can not export to, due to regulatory restrictions. At the same time, we will continue to regularly manufacture and export our medical cannabis products to Germany, France and Cyprus from our facility in Israel, the only one in the country with EU-GMP standard. ”
Panaxia now owns two facilities with the exclusive and sought-after European standard, which will allow it to export its products to a wider variety of countries.
The EU-GMP standard for a production facility in Malta was adopted shortly after obtaining a marketing permit for cannabis extracts for vaporization in Germany. Following this permit, Panaxia Israel has become the first and only company to export and market medical cannabis extracts for vaporization in Germany, in particular and in Europe, in general. In addition, Panaxia is the only company in Europe to have a regulatory permit for the distribution of medical cannabis tablets in France, as part of the French National Agency for Medicines and Health Products Safety (ANSM).
For more information: 
Panaxia
panaxia.co.il